Wuhan Hvsen Biotechnology Co Ltd Cash Flow-to-Debt Ratio
Wuhan Hvsen Biotechnology Co Ltd cash flow-to-debt ratio. Wuhan Hvsen Biotechnology Co Ltd (300871) has a Cash Flow-to-Debt Ratio of 0.07x as of September 2025, meaning its operating cash flow of CN¥59.06 Million could theoretically repay 0% of its total liabilities (CN¥839.94 Million) in one year. Check Wuhan Hvsen Biotechnology Co Ltd (300871) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Wuhan Hvsen Biotechnology Co Ltd (2016–2025)
Cash flow-to-debt ratio of Wuhan Hvsen Biotechnology Co Ltd from 2016 to 2025. Historical debt coverage capacity for Wuhan Hvsen Biotechnology Co Ltd across 10 annual periods. Check 300871 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Wuhan Hvsen Biotechnology Co Ltd Cash Flow-to-Debt Ratio by Year (2016–2025)
Wuhan Hvsen Biotechnology Co Ltd cash flow-to-debt ratio by year from 2016 to 2025. Year-by-year debt coverage analysis for Wuhan Hvsen Biotechnology Co Ltd. For the full cash flow conversion analysis, see cash flow conversion of Wuhan Hvsen Biotechnology Co Ltd.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.29x | CN¥238.45 Million | CN¥822.17 Million | ▲ +932.3% |
| 2024 | 0.03x | CN¥43.53 Million | CN¥1.55 Billion | ▼ -55.7% |
| 2023 | 0.06x | CN¥92.92 Million | CN¥1.47 Billion | ▼ -5.1% |
| 2022 | 0.07x | CN¥96.68 Million | CN¥1.45 Billion | ▼ -51.8% |
| 2021 | 0.14x | CN¥155.72 Million | CN¥1.12 Billion | ▲ +7.0% |
| 2020 | 0.13x | CN¥48.35 Million | CN¥373.08 Million | ▼ -66.5% |
| 2019 | 0.39x | CN¥105.24 Million | CN¥271.80 Million | ▲ +160.8% |
| 2018 | 0.15x | CN¥21.10 Million | CN¥142.08 Million | ▼ -77.7% |
| 2017 | 0.67x | CN¥80.56 Million | CN¥121.06 Million | ▲ +12.2% |
| 2016 | 0.59x | CN¥60.00 Million | CN¥101.16 Million | — |